APA (7th ed.) Citation

Tuttle, K. R., Levin, A., Nangaku, M., Kadowaki, T., Agarwal, R., Hauske, S. J., . . . Wheeler, D. C. (2022). Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: Pooled analysis of placebo-controlled clinical trials : cardiovascular and metabolic risk. Diabetes care, 45(6), . https://doi.org/10.2337/dc21-2034

Chicago Style (17th ed.) Citation

Tuttle, Katherine R., et al. "Safety of Empagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-controlled Clinical Trials : Cardiovascular and Metabolic Risk." Diabetes Care 45, no. 6 (2022). https://doi.org/10.2337/dc21-2034.

MLA (9th ed.) Citation

Tuttle, Katherine R., et al. "Safety of Empagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-controlled Clinical Trials : Cardiovascular and Metabolic Risk." Diabetes Care, vol. 45, no. 6, 2022, https://doi.org/10.2337/dc21-2034.